article thumbnail

New legislation is a great first step to lower drug prices

World of DTC Marketing

Most adults – across partisans – don’t believe high drug prices are needed for drug companies to invest in new research instead agreeing that “even if U.S. prices were lower, drug companies would still make enough money to invest in the research needed to develop new drugs.”.

Marketing 158
article thumbnail

2022 in review: Regulation starts to catch up with AI in pharma

Pharmaceutical Technology

Artificial intelligence (AI) continued to stay in the news with several high-profile deals this year, as the pharmaceutical industry readily took to adopting AI models to improve drug discovery. GlobalData is the parent company of Pharmaceutical Technology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

PharmaKinnex

The pharmaceutical industry of 2022 is very different from the space that we all knew in 2012, 2016, or even 2020. The Traditional Pharma Model Isn’t Working – It’s Time to Evolve! August 23, 2022. dstansberry@costellocreativegroup.com.

article thumbnail

The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

PharmaKinnex

The pharmaceutical industry of 2022 is very different from the space that we all knew in 2012, 2016, or even 2020. The Traditional Pharma Model Isn’t Working – It’s Time to Evolve! August 23, 2022. dstansberry@costellocreativegroup.com.

article thumbnail

Pharma’s ESG goals need to underscore push for health equity

Pharmaceutical Technology

Over recent years, many pharmaceutical companies have taken up environment, social and governance (ESG) targets in order to prioritize sustainability whilst boosting their external public relations. GlobalData is the parent company of Pharmaceutical Technology.

article thumbnail

US Democrats’ blockbuster budget bill could spell big changes for drug prices

Pharma Phorum

Chief among these provisions is that the bill will allow, and indeed require, Medicare, the US’s government-run insurance program for older Americans, to negotiate drug prices with pharmaceutical companies in some cases, something it historically has not been allowed to do.